Associations between the Genetic Polymorphisms of Osteopontin Promoter and Susceptibility to Cancer in Chinese Population: A Meta-Analysis

Abstract

Background and AimSeveral studies have been conducted to examine the associations between osteopontin (OPN) promoter gene SPP1 polymorphisms with human cancers in Chinese population, but the results remain inconsistent. The aim of this meta-analysis is to clarify the associations between SPP1 polymorphisms and cancer susceptibility.MethodsAll eligible case-control studies published up to March 2015 were identified by searching PubMed, Web of Science, Embase, and Cochrane Library without language restrictions. Pooled odds ratio (OR) and 95% confidence interval (95% CI) were calculated using fixed- or random-effect model.ResultsA total of 11 case-control studies were included; of those, there were eleven studies (3130 cases and 3828 controls) for -443T>C polymorphism, ten studies (3019 cases and 3615 controls) for -156G>GG polymorphism, eight studies (2258 cases and 2846 controls) for -66T>G polymorphism. Overall, no evidence indicated that the -443 T>C polymorphism was associated with cancer risk (OR = 0.93, 95%CI 0.62–1.38 for dominant model, OR = 1.06, 95%CI 0.73–1.55 for recessive model, OR = 0.88, 95%CI 0.62–1.26 for CT vs TT model, OR = 1.03, 95%CI 0.61–1.73 for CC vs TT model). While, a significantly increase risk was found for -156 G>GG polymorphism (OR = 1.22, 95%CI 1.10–1.35 for dominant model, OR = 1.25, 95%CI 1.10–1.41 for recessive model, OR = 1.18, 95%CI 1.06–1.32 for GGG vs GG model, OR = 1.35, 95%CI 1.09–1.68 for GGGG vs GG model). For -66T>G polymorphism, we found a decrease risk of cancer (OR = 0.84, 95% CI 0.71–0.98 for dominant model), but this result changed (OR = 0.93, 95% CI 0.77–1.12 for dominant model) when we excluded a study.ConclusionThis meta-analysis suggests that in Chinese population the -156G>GG polymorphism of SPP1 might be a risk factor for human cancers, while -443T>C mutation is not associated with cancer risk. For -66T>G polymorphism, it may be a protective factor for human cancers.

Genetic Modifiers of Duchenne Muscular Dystrophy in Chinese Patients

“…All three SPP1 promoter SNPs at−66,−156, and−443 have been surveyed simultaneously in several diseases, including ischemic stroke ( 10 ), glioma ( 15 ), osteoarthritis ( 12 ), cervical spondylotic myelopathy ( 13 ), and a variety of cancers ( 11 , 14 ). It had also been proved that the haplotype−443T/-156GG/-66G appear to significantly lower promoter activity in comparison to the other five haplotypes ( 40 ).…”

Common Variants in Osteopontin and CD44 Genes as Predictors of Treatment Outcome in Radiotherapy and Chemoradiotherapy for Non-Small Cell Lung Cancer

“…However, in the case of other solid tumors, such as, e.g., glioma or oral, nasopharyngeal, hepatocellular, and breast cancers, variant C was protective in terms of cancer risk or prognosis [36,[46][47][48][49]. The results of a meta-analysis based on 11 studies in the Chinese population, including the NSCLC study, suggested in turn that rs11730582 had no effect on cancer risk [50].…”

Prognostic value of Osteopontin (SPP1) in colorectal carcinoma requires a personalized molecular approach

“…[44][45][46][47] While the -156G.GG polymorphism of spp1 gene is associated with high cancer risk, the presence of -66T.G SNP may act as a protective factor for human cancers; whereas -443T.C mutation in spp1 promoter is not associated with cancer risk. 46 In case of CRC, mutations in spp1 promoter (rs9138 and rs1126616) were shown to be significant contributors to increased risk of developing CRC. 42,44 Similarly, the presence of spp1 promoter SNPs -443 (rs11730582) and -1748 (rs2728127) was associated with the aggressiveness of breast cancer.…”

“…42,43 In fact, SPP1 isoforms mainly SPP1c was associated with worse survival outcomes. [44][45][46][47] While the -156G.GG polymorphism of spp1 gene is associated with high cancer risk, the presence of -66T.G SNP may act as a protective factor for human cancers; whereas -443T.C mutation in spp1 promoter is not associated with cancer risk. 46 In case of CRC, mutations in spp1 promoter (rs9138 and rs1126616) were shown to be significant contributors to increased risk of developing CRC.…”